Answers are grounded in this paper and cite their sources.
Demonstrates antitumor activity of crizotinib in advanced ROS1-rearranged NSCLC, highlighting treatment potential.
In this study, crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC. ROS1 rearrangement defines a second molecular subgroup of NSCLC for which crizotinib is highly active. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).
No takes yet. Share an insight, caveat, or question.
Shaw et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: